Viking Therapeutics, Inc. Aktie News

Konferenzschaltung für heute um 16:30 Uhr ET geplant -- Phase‑3‑Studien VANQUISH 1 & 2 für subkutanes VK2735 bei Adipositas vollständig eingeschrieben und in der Durchführung -- -- Beginn der oralen Phase‑3‑Studie zu VK2735 erwartet 4Q26 -- -- VK2735‑Erhaltungsdosisdaten erwartet 3Q26 -- -- Phase‑1‑Studie des Amylin‑Agonisten VK3019 läuft -- -- Starker Quartalsend‑Kassenbestand von 502 Mio. USD...

Erfahrene Managerin bringt mehr als zwei Jahrzehnte Führungserfahrung in den Bereichen Gesundheitswesen, Digital Health und Kommerzialisierung SAN DIEGO, 23. Juli 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung neuartiger Therapien für Stoffwechsel- und endokrine Erkrankungen konzentr...

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced to...

Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Hubert C. C...

SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference in June. Details of the company...

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13 Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second po...

Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announ...